Cancer discovery news
Our researchers are making the discoveries that defeat cancer. Read the latest findings from our world-leading research.
Visit our main news hub to read about news on new funding, our fundraising activities and much more. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
Scientists uncover promising new treatment strategy for aggressive form of leukaemia
Scientists have uncovered a promising treatment strategy for an aggressive type of leukaemia – through targeting the enzymes that cells normally use to sense and adapt to changing oxygen levels.
Scientists discover how some advanced breast cancers become resistant to hormone therapy
New research has identified why some advanced oestrogen receptor (ER) positive breast cancers become resistant to hormone therapy, and has identified drugs currently in development that could keep disease stable for longer for these patients.
Scientists now able to predict response to radium-223 treatment in prostate cancer bone metastases
Researchers have found a way to predict which patients are likely to respond to radium-223, a standard treatment for advanced prostate cancer that has spread to the bones.
Next-generation trial shows five-drug combo can keep ‘ultra-high-risk’ bone marrow cancer at bay
Combining five existing drugs can keep a highly aggressive type of bone marrow cancer at bay for longer, an innovative trial has shown.
ICR-discovered drug to enter phase II clinical trial in ovarian cancer thanks to new research collaboration
An innovative cancer drug discovered by scientists at The Institute of Cancer Research, London, is set to enter a new clinical trial.
-547x410.jpg?sfvrsn=5e98f2c_2 "Clinical trials pharmacy (Jan Chlebik for the ICR, 2014) 547x410")
Innovative first in class HSF1 pathway cancer drug shows strong results in new study
A new, oral ‘first in class’ experimental cancer drug has shown potent activity against cancer cells and caused shrinkage of hard-to-treat human ovarian tumours grown in mice, a new study shows.
Genetic test can guide treatment for blood cancer to help prevent relapse
Scientists have found a new way to predict which patients with the blood cancer myeloma will benefit the most from a treatment often used to help keep the disease from coming back after a bone marrow transplant.
‘Molecular glue degrader’ reaches cancer trial following ICR research programme
The biotechnology company Monte Rosa Therapeutics – originally a spin-out from research at The Institute of Cancer Research, London – has announced that the first patient has received their ‘molecular glue degrader’ drug as part of a clinical trial in oncology.
Study opens route to overcoming drug resistance in stomach cancer
Scientists have shown how stomach cancers can dodge the effects of a promising new experimental treatment – raising the possibility of outsmarting cancer by predicting drug resistance in advance.
First Covid jab provides protection for most myeloma blood cancer patients
A single dose of a Covid-19 vaccine triggers an immune response in around 70 per cent of patients with myeloma – suggesting that it does provide protection against the virus.
Resistance-busting ICR drug enters clinical trial
A drug discovered at The Institute of Cancer Research that could counteract drug resistance in patients with cancers including acute myeloid leukaemia has entered a phase I clinical trial at The Royal Marsden NHS Foundation Trust.
Researchers reveal discovery of new cancer drug fadraciclib
Scientists have revealed details of the discovery of a new cancer drug that could be used to treat a range of cancer types, including some blood cancers and solid tumours.